CN1235620C - 一种治疗缺血性中风的药物及其制备方法 - Google Patents
一种治疗缺血性中风的药物及其制备方法 Download PDFInfo
- Publication number
- CN1235620C CN1235620C CNB031450369A CN03145036A CN1235620C CN 1235620 C CN1235620 C CN 1235620C CN B031450369 A CNB031450369 A CN B031450369A CN 03145036 A CN03145036 A CN 03145036A CN 1235620 C CN1235620 C CN 1235620C
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- roots
- treatment
- relative density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 229940079593 drug Drugs 0.000 title description 6
- 238000000034 method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 title 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000341 volatile oil Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 34
- 206010008118 cerebral infarction Diseases 0.000 claims description 13
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 241000237636 Pheretima Species 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 abstract description 11
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 241001061264 Astragalus Species 0.000 abstract 2
- 241000555712 Forsythia Species 0.000 abstract 2
- 241000405414 Rehmannia Species 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 241001233061 earthworms Species 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 238000000605 extraction Methods 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 210000004233 talus Anatomy 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010063900 Steal syndrome Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 241000294142 Vascellum Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000010225 buchang naoxintong Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003861 dual diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | N | 基本痊愈 | 显效 | 有效 | 无效 | 有效率 |
治疗组 | 30 | 15 | 8 | 6 | 1 | 97% |
对照组 | 30 | 9 | 6 | 10 | 5 | 83% |
组别 | 高切(200/S) | 低切(10/S) | 血浆粘度(mpa.s) | 红细胞压积 | |
治疗组 | 治疗前 | 6.44±1.13△ | 9.53±1.98△ | 1.69±0.18△ | 48.83±6.23△ |
治疗后 | 5.58±0.97△ | 7.82±1.53△ | 1.58±0.13△ | 41.60±4.34△ | |
对照组 | 治疗前 | 6.45±1.13△ | 9.56±2.00△ | 1.70±0.19△ | 47.8±6.35△ |
治疗后 | 5.64±1.02△ | 7.79±1.62△ | 1.53±0.13 | 42.6±4.45△ |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031450369A CN1235620C (zh) | 2003-06-18 | 2003-06-18 | 一种治疗缺血性中风的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031450369A CN1235620C (zh) | 2003-06-18 | 2003-06-18 | 一种治疗缺血性中风的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1565580A CN1565580A (zh) | 2005-01-19 |
CN1235620C true CN1235620C (zh) | 2006-01-11 |
Family
ID=34471337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031450369A Expired - Lifetime CN1235620C (zh) | 2003-06-18 | 2003-06-18 | 一种治疗缺血性中风的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1235620C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107551131A (zh) * | 2017-09-06 | 2018-01-09 | 浙江中医药大学 | 一种治疗缺血性中风的中药组合 |
-
2003
- 2003-06-18 CN CNB031450369A patent/CN1235620C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107551131A (zh) * | 2017-09-06 | 2018-01-09 | 浙江中医药大学 | 一种治疗缺血性中风的中药组合 |
CN107551131B (zh) * | 2017-09-06 | 2020-12-29 | 浙江中医药大学 | 一种治疗缺血性中风的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1565580A (zh) | 2005-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1298362C (zh) | 一种治疗盆腔炎的中药复方制剂及其制备方法 | |
CN1235620C (zh) | 一种治疗缺血性中风的药物及其制备方法 | |
CN1899518A (zh) | 一种治疗烧烫伤的外用中药及其制备方法 | |
CN1506098A (zh) | 一种治疗肝纤维化和肝硬化的药物组合物及其制备方法 | |
CN102614470B (zh) | 治疗中风后遗症外用中草药组合物 | |
CN1440804A (zh) | 一种降血脂的中药 | |
CN1281241C (zh) | 一种治疗慢性支气管炎的药物及其制备方法 | |
CN1481870A (zh) | 一种治疗顽固性慢性便秘的复方中药制剂及其制备方法 | |
CN1907345A (zh) | 一种治疗脑中风的中药组合物 | |
CN1895364A (zh) | 一种治疗脑血栓后遗症、风湿性关节炎的夏天无药物组合物 | |
CN101732688B (zh) | 一种含有氨氯地平的药物 | |
CN101773657B (zh) | 一种含有硝普钠的药物 | |
CN1857531A (zh) | 一种治疗糖尿病视网膜病变的中药制剂处方、制备方法及其应用 | |
CN100475248C (zh) | 一种治疗子宫出血的药物及其制备工艺 | |
CN1207050C (zh) | 治疗慢性鼻炎的中药及其生产方法 | |
CN1091382C (zh) | 一种治疗血管神经性头痛的药物及其制备方法 | |
CN100367956C (zh) | 用于治疗高血压的药物 | |
CN101732689B (zh) | 一种含有米诺地尔的药物 | |
CN100367959C (zh) | 一种含有依贝沙坦的药物 | |
CN1114420C (zh) | 治疗顽固性坐骨神经痛、慢性腰腿痛的药物及其制备方法 | |
CN115887590A (zh) | 一种治疗银屑病的蒙药药浴组合物、其制备方法及应用 | |
CN101810839B (zh) | 一种含有地尔硫卓的药物 | |
CN101732687B (zh) | 一种含有甲基多巴的药物 | |
CN1274332C (zh) | 治疗中风先兆的药物制剂及其制备方法 | |
CN101502635B (zh) | 一种含利血平的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YABAO GROUP TAIYUAN PHAMACEUTICAL CO.,LTD Free format text: FORMER OWNER: LUO CHUNXIU Effective date: 20060707 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060707 Address after: 037043 No. 20 Dayun Road, Taiyuan economic and Technological Development Zone Patentee after: TAIYUAN YABAO PHARMACEUTICAL Co.,Ltd. Address before: 100089 Beijing city Haidian District landianchang road 10F-1023 No. 25 Newton office room Patentee before: Luo Chunxiu |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060111 |
|
DD01 | Delivery of document by public notice |
Addressee: Yang Aiping Document name: Notice of Termination of Patent Rights |
|
DD01 | Delivery of document by public notice |